Urolithin A: The Mitophagy Compound Your Gut May Not Be Making

The Gut Metabolite Behind the Mitophagy Story

Urolithin A is a dibenzo[b,d]pyran-6-one polyphenol metabolite. It is produced when gut bacteria convert dietary ellagitannins — found in pomegranates, walnuts, strawberries, raspberries, and certain oak-aged wines — into bioactive urolithins. Only about 40% of adults harbor the gut microbiome capable of producing urolithin A from those dietary precursors.

Urolithin A is the major bioactive metabolite of ellagic acid and ellagitannin metabolism in the human gut. Urolithin A's impact on health, disease, and aging has become one of the more scientifically substantive stories in the longevity-supplement space. The marketing-relevant distinction is this: ellagic acid and ellagitannins are precursors. Urolithin A is the active form. Whether that conversion actually happens depends entirely on the individual's gut microbiome composition.

Chemistry: from ellagic acid to dibenzopyranone

Urolithin A belongs to the urolithin family — a group of dibenzo[b,d]pyran-6-one compounds produced from ellagic-acid metabolism. The family includes urolithins A, B, C, D, and G. The hydroxyl pattern on the dibenzopyranone scaffold is what determines bioactivity. Urolithin A (UroA) is the most extensively studied. Urolithin G was recently identified as a metabolite driven by intestinal Enterocloster species, adding another layer to the conversion story.

The structural specificity matters because not all urolithins are equivalent. Urolithin A stands out as the most bioactive member of this metabolite family, which is why the supplement market has converged on it specifically rather than on ellagic acid or mixed urolithin extracts.

From pomegranate folklore to mitophagy biology

Dietary ellagitannins from pomegranates, walnuts, and berries (strawberry, raspberry, blackberry) are hydrolyzed in the gut to ellagic acid. Specific gut bacteria — primarily Gordonibacter and Enterocloster species — carry out the microbial conversion of ellagic acid to urolithins. The modern urolithin A story begins with a landmark 2016 paper: urolithin A induced mitophagy, extended lifespan in C. elegans, and improved muscle function in rodents.

The supplement market followed quickly. The driver was the variability finding: inter-individual differences in polyphenol metabolism are substantial, meaning dietary ellagitannin intake is an unreliable route to urolithin A exposure for most adults.

Urolithin A: From Gut Conversion to Mitochondrial Quality Control

The dominant proposed mechanism is mitophagy — the selective autophagy of damaged mitochondria. This process declines with age and is implicated in muscle, immune, and cellular-quality-control deterioration. Both the foundational preclinical work and the first human trials point to mitophagy activation as urolithin A's primary biological lever.

Mechanism: mitophagy activation in cells, rodents, and humans

Urolithin A is proposed to induce mitophagy via PINK1/Parkin-dependent and -independent pathways. The original preclinical demonstration showed selective clearance of damaged mitochondria in C. elegans and mice. Neuronal mitophagy biology provides additional mechanistic context for why this pathway is relevant across tissue types. Mitophagy is now recognized as a therapeutic target in age-related pathologies — not a fringe idea.

Mitophagy clears damaged mitochondria and supports mitochondrial biogenesis. Urolithin A induces time-dependent alterations in mitochondrial biogenesis in muscle cells, alongside other mitophagy activators. In humans, the 2019 first-in-human RCT documented a molecular signature of improved mitochondrial and cellular health — specifically, acylcarnitine shifts and skeletal-muscle gene-expression changes consistent with mitophagy activation in healthy elderly adults. The mitophagy-marker activation is established at the human-biomarker level. Whether it translates to clinically meaningful aging outcomes is still being mapped.

Pharmacokinetics: oral bioavailability and microbiome dependency

Direct urolithin A is orally bioavailable. Plasma urolithin A and its glucuronide conjugate were measurable across single-ascending-dose and repeat-dosing arms in the first-in-human trial, with a Tmax of approximately 3 to 5 hours. The parent compound and conjugated metabolites circulate at quantifiable concentrations. Dosing with fat-containing food is standard in trials, consistent with the compound's lipophilic character.

The key pharmacokinetic distinction is the microbiome-conversion bottleneck. For dietary precursors, approximately 10% of people cannot produce urolithin A at all, and only about 40% are reliable producers. Direct urolithin A supplementation overcomes the gut-microbiome variability that limits production from dietary sources. Sex-based differences in urolithin production from dietary ellagic acid are also documented, adding another layer of inter-individual variability to the dietary-precursor route.

What the Urolithin A Evidence Actually Shows

Urolithin A occupies an unusual position in the supplement landscape. The mechanism is well-characterized in animals and, at the biomarker level, in humans. But clinical-endpoint evidence is still maturing, and sample sizes across published RCTs are modest. Grading each claim separately is the most honest approach.

Evidence grades used in this section:

• Strong: >=2 well-designed RCTs in humans on a clinically meaningful endpoint, ideally with a meta-analysis showing a consistent direction of effect. Or a single very large RCT (N>1,000) with replicable methodology.
• Moderate: >=1 RCT in humans with a clinically meaningful endpoint, OR multiple smaller RCTs with mixed results, OR a single high-quality RCT on a surrogate endpoint.
• Limited: Only small (N<50), short (<8 weeks), or methodologically weak human trials; or only observational evidence in humans.
• Animal-only / Preclinical: No completed human trials. In-vitro, animal-model, or Phase 1 safety data only.
• Anecdotal: No controlled evidence of any kind — case reports, testimonials, mechanistic plausibility, or marketing claims unsupported by published data.

Mitophagy-marker activation in human RCTs — Moderate

A 2019 first-in-human RCT in healthy elderly adults induced acylcarnitine and gene-expression changes consistent with improved mitochondrial and cellular health. A subsequent RCT in older adults (n=66, mean age 71.7) documented reductions in inflammatory and cellular-stress biomarkers at four months. The 2022 ATLAS trial in middle-aged adults showed reduced acylcarnitines and CRP at four months. The mitophagy and mitochondrial-marker activation signal is consistent across these small RCTs. Sample sizes remain modest, and the clinical translation of these biomarker shifts is not yet fully characterized.

Muscle function in older and middle-aged adults: modest, directionally consistent — Moderate

In older adults (n=66, mean age 71.7, four months), urolithin A improved muscle endurance but did not significantly improve walking distance or ATP production vs. placebo. The 2022 ATLAS trial (n=88, middle-aged adults, four months) showed approximately 12% improvement in muscle strength, improved peak oxygen consumption, and better 6-minute walk performance — but peak power, the primary endpoint, did not reach statistical significance. Secondary-endpoint signals across two RCTs are consistently positive. Primary endpoints have not consistently reached significance. The muscle-function evidence is genuinely modest but directionally coherent.

Urolithin A and cellular, immune, and cardiovascular endpoints in aging — Limited

The most current human RCT examined urolithin A for age-related immune decline, representing the leading edge of this evidence base. At the mechanistic level, urolithin A-induced mitophagy has been shown to expand T memory stem cells with implications for anti-tumor immunity. On the cardiovascular side, preclinical and translational work suggests cardioprotective effects and improvements in cardiovascular biomarkers — though this remains early-stage. Urolithin A is one of several nutritional approaches being investigated for mitochondrial support in aging muscle. Human evidence on cellular and immune endpoints is emerging but not yet at the strength of the mitophagy-marker or muscle-function data.

Urolithin A extends lifespan or reverses aging in humans — Animal-only

Lifespan extension in C. elegans and improved muscle function in rodents represent strong preclinical work — and that is where the lifespan evidence stops. No human evidence of lifespan extension or epigenetic-age reversal at clinically meaningful effect sizes exists in long-term controlled studies. Marketing claims of "longevity" or "reverses aging" extrapolate from preclinical lifespan data to human aging biomarkers without controlled-trial support on hard endpoints. This is not shown in humans.

Urolithin A improves athletic performance in healthy young athletes — Limited

A pilot RCT in male academy soccer players (n=20, six weeks, 1,000 mg/day) showed improved Yo-Yo IRT1 performance and countermovement jump vs. placebo. This is a single small pilot study and has not yet been replicated in larger athletic populations. The signal is interesting; the evidence base is thin.

What urolithin A is not shown to do: Urolithin A is not shown to extend human lifespan. It is not shown to reverse aging or produce clinically meaningful changes in epigenetic age over long-term human studies. It is not shown to prevent or treat sarcopenia, Alzheimer's disease, osteoarthritis, or any specific clinical condition in humans. It is not a substitute for resistance training, which remains the strongest evidence-based intervention for muscle preservation in aging. It does not carry an FDA-approved indication for any use.

Direct Urolithin A vs. Precursor Sources: Why Form Matters

For urolithin A specifically, form is not a minor detail — it determines whether the target compound reaches circulation at all. The headline distinction is direct urolithin A versus ellagitannin precursors from pomegranate or walnut sources. The latter depend on gut-microbial conversion that fails in approximately 60% of adults.

• Direct urolithin A (e.g., Mitopure by Amazentis/Timeline Nutrition). The branded form with the published human RCT base spanning the 2019 first-in-human trial, the 2022 older-adult RCT, the 2022 ATLAS trial in middle-aged adults, and the 2025 immune-decline trial. Typical studied doses range from 500 to 1,000 mg/day. Pharmacokinetic studies establish oral bioavailability. The FDA issued a ‘no questions’ letter in 2018; EFSA Novel Food authorization followed in 2021. When evaluating any direct urolithin A product, documented PK data on the specific source is the key quality marker.
• Pomegranate ellagic acid and ellagitannin extracts. These are precursor compounds whose conversion to urolithin A depends entirely on gut-microbial composition. Approximately 40% of adults produce measurable urolithin A from these sources; approximately 10% produce none at all. Bioavailability of urolithin A from precursors is highly variable. These extracts are a reasonable dietary-pattern input but are suboptimal if direct urolithin A exposure is the goal and producer status is unknown.
• Walnut and berry-based whole-food sources. Whole-food ellagitannin sources carry the same gut-conversion dependency. They deliver broader nutritional benefit — fiber, healthy fats, additional polyphenols — as part of a Mediterranean-pattern diet. They are not a substitute for direct urolithin A if mitophagy activation is the specific objective.

Third-party testing matters for any direct urolithin A product. Look for USP, NSF International, or ConsumerLab verification where available. Standardization markers to prioritize: documented purity, published PK data, and the source company's RCT publication record. Quality flags to watch for include generic "urolithin A" capsules with no batch testing or PK documentation; "pomegranate extract" products marketed as equivalent to direct urolithin A; and proprietary blends combining urolithin A with unstudied co-ingredients that would confound any expected effect.

Urolithin A Regulatory Status (as of May 2026)

As of May 2026, urolithin A is sold in the United States as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved for any clinical indication. No New Drug Application has been filed for any specific therapeutic use. Mitopure, the Amazentis/Timeline Nutrition branded direct urolithin A, achieved FDA Generally Recognized as Safe (GRAS) status in 2020 and received EFSA Novel Food authorization in 2021 — both specific to that source and manufacturing process. No FDA warning letters specific to urolithin A products are on record as of this article's last-updated date. WADA does not list urolithin A as a prohibited substance; athletes in tested sport should independently confirm current status before use, as prohibited-substance lists are updated periodically.

Urolithin A Safety and Drug Interactions

Urolithin A has been studied at doses of 250 to 1,000 mg/day for up to four months across published RCTs, with a favorable tolerability profile in those trials. Long-term human safety data beyond 12 months does not yet exist. The most clinically relevant safety questions involve theoretical interactions with medications that affect mitochondrial function.

Reported side effects in urolithin A trials

The 2019 first-in-human trial documented tolerability up to 1,000 mg/day across single-ascending-dose and four-week repeat-dosing arms. Across the 2022 older-adult trial and the ATLAS trial, the most commonly reported adverse events were mild and transient — GI symptoms, headache, and fatigue at rates comparable to placebo, with favorable tolerability in middle-aged adults. Trials have documented a favorable short-term tolerability profile — not a clean bill of health for all populations and durations. The absence of large, long-term safety data is a genuine limitation; the longest published RCTs run four months.

Urolithin A drug interactions

• Statins — Moderate (theoretical). Statins have documented mitochondrial-function effects, including complex-I inhibition. Co-administration with a mitophagy activator may modify the muscular tolerability profile of statins. Mitophagy is implicated in the cellular response to mitochondrial stress, which is mechanistically relevant here. Discuss with the prescribing clinician before combining.
• Metformin — Minor (theoretical). Metformin has documented complex-I and mitochondrial effects. Co-administration with a mitophagy modulator is mechanistically plausible to interact, though clinical relevance has not been established in controlled studies.
• Antiretrovirals (NRTIs) — Minor (theoretical). NRTIs carry known mitochondrial-toxicity profiles. Mitophagy modulation could theoretically alter that interaction, though no clinical data exist to characterize the magnitude.
• Immunosuppressants — Minor (theoretical). Urolithin A-induced mitophagy modulates T-cell biology, which creates a theoretical interaction with immunosuppressant pharmacology. Discuss with the prescribing clinician before combining.

Most listed interactions are mechanistically theoretical, not clinically documented. The absence of a documented interaction does not mean the combination is safe — it means it has not been studied.

Pregnancy, breastfeeding, and special populations

Pregnancy and breastfeeding: avoid supplemental urolithin A. No controlled human safety data exist at supplemental doses, and mitophagy modulation during fetal development is uncharacterized. For hepatic impairment: urolithin A and its metabolites are partially conjugated hepatically — caution is warranted at the higher dose range, though specific guidance is absent from published literature. For renal impairment: glucuronidated metabolites are renally cleared; no dose-adjustment guidance exists in the published literature, but caution is appropriate in advanced chronic kidney disease. Children and adolescents: supplemental doses are not characterized in pediatric populations; no pediatric trials have been conducted. Anyone with a documented mitochondrial disease should not use urolithin A without specialist consultation.

Who Should Skip Urolithin A

The following represent honest contraindications and high-caution populations based on the current evidence base and mechanistic considerations.

• Pregnant or breastfeeding individuals — no controlled human safety data at supplemental doses.
• Anyone on statins, metformin, NRTIs, or immunosuppressants without prescriber sign-off — theoretical mitochondrial interactions.
• Anyone with documented mitochondrial disease — specialist consultation first.
• Anyone with advanced chronic kidney disease — no controlled data on glucuronide clearance at the higher dose range.
• Children and adolescents — supplemental doses are not characterized in pediatric populations.
• Anyone with hypersensitivity to pomegranate or ellagitannin sources.

If any of the above apply, do not start urolithin A without speaking to a clinician familiar with your full medication list and biomarkers.

Why ~60% of Adults Don't Get Urolithin A From Food

The practical question is straightforward: does eating pomegranates and walnuts deliver the same urolithin A exposure as a direct supplement? For most adults, the answer is no. Approximately 40% of adults are reliable urolithin A producers, roughly 50% are low-producers, and about 10% produce none at all from dietary precursors. Direct supplementation bypasses this entirely.

• Source and chemistry. Direct urolithin A is the bioactive metabolite itself, manufactured by chemical synthesis. Ellagic-acid precursors are pomegranate, walnut, and berry-derived ellagitannins hydrolyzed in the gut to ellagic acid, then microbially converted to urolithins by specific Gordonibacter and Enterocloster species.
• Bioavailability. Direct urolithin A: orally bioavailable with measurable plasma exposure documented in clinical trials. Precursors: bioavailability of resulting urolithin A varies substantially, with sex differences documented alongside microbiome-composition differences.
• Strongest evidence. Direct urolithin A: human RCTs on mitophagy markers, muscle function, and immune endpoints. Precursors: dietary-pattern evidence for ellagitannin-rich foods in a Mediterranean-pattern context; no controlled trials of precursor supplementation that produce equivalent urolithin A exposure across all participants.
• Studied dose range. Direct urolithin A: 250 to 1,000 mg/day for four months in published RCTs. Pomegranate and walnut precursors: not directly comparable; food-quantity equivalents sufficient to deliver 500 mg urolithin A exposure are not practical even in reliable producers.
• Key safety differences. Direct urolithin A: FDA GRAS status (2020) and EFSA Novel Food authorization (2021) for the Mitopure source. Precursors: long history of food consumption with broader nutritional benefit from the parent foods.
• Cost (relative). Direct urolithin A: $$$. Precursor extracts: $$. Whole foods: $.
• Regulatory status. Both: US dietary supplements under DSHEA. Mitopure direct urolithin A: GRAS and EFSA Novel Food authorized. Neither is FDA-approved for any clinical indication as of May 2026.

For someone whose primary interest is mitophagy activation or muscle function and who doesn't know their producer status, direct urolithin A removes the gut-microbiome conversion variable entirely. For someone whose primary interest is broader Mediterranean-pattern healthspan, dietary ellagitannin sources — pomegranates, walnuts, berries — deliver the full polyphenol nutritional profile alongside whatever urolithin A their microbiome produces. Direct supplementation produces more consistent urolithin A exposure than precursor sources for the ~60% of adults who are not reliable producers. The biomarker that would actually answer this question for a specific individual is urinary urolithin A status after a pomegranate-juice or walnut-loading test — that tells you whether you're already a producer.

Direct Mitophagy Biomarkers Aren't Standard, but Functional and Inflammatory Readouts Are

Direct mitophagy biomarkers are not yet routine clinical tests. The practical readouts are functional (muscle performance, athletic capacity), inflammatory (hs-CRP), and where assays are available, mitochondrial-function markers. A comparable Day 0 and Day N panel is the only way to distinguish a supplement response from placebo effect, training adaptation, or regression to the mean.

• hs-CRP: The 2022 ATLAS trial showed reduced CRP at four months; a separate older-adult RCT also documented reductions in inflammatory biomarkers. hs-CRP is the most accessible systemic readout for whether urolithin A is doing anything measurable in your physiology.
• Grip strength and 6-minute walk distance: the functional readouts the ATLAS RCT measured directly — muscle strength improvement of approximately 12% and 6-minute walk improvement. Most relevant for older and middle-aged adults targeting muscle function. Both are bedside-measurable.
• Body composition (DEXA where available): appendicular lean mass and total lean mass are the most direct muscle-mass readouts. Body composition remodels slowly — a minimum of 12 weeks is needed to see meaningful change.
• Acylcarnitine profile (where the lab offers it): acylcarnitine shifts were the primary mitochondrial-function readout in the first-in-human trial. Not all labs offer this panel; availability should be confirmed before using it as a baseline marker.
• Lactate (post-exercise where assay is available): the 2022 ATLAS trial documented peak VO2 changes; lactate kinetics during standardized exercise are an indirect mitochondrial-function readout that can be tracked over time.
• Producer-status testing (urinary urolithin A after a pomegranate or walnut load): the most useful pre-supplementation test. It tells you whether you're already a urolithin A producer from dietary precursors. Available through specialty labs.

When Symptoms Need a Workup, Not a Supplement

If the reason for reaching for urolithin A is suspected sarcopenia, unexplained muscle weakness, exercise intolerance, or persistent fatigue, those symptoms deserve a primary-care evaluation first. That means metabolic and inflammatory bloodwork, plus age- and risk-appropriate workups covering thyroid, cardiovascular, and neurologic function. The clinical pathway is a primary-care visit with a broader fatigue and muscle-function workup; a physical therapy or strength-training evaluation for muscle-function concerns; and a sleep-medicine consult if exercise intolerance is accompanied by daytime sleepiness. A supplement experiment is not a substitute for that workup.

Measuring biology before acting on it — and re-measuring afterward — is the foundation of Superpower's approach to preventive health. In a supplement market this new and this enthusiastic about a real but young evidence base, a measured baseline is the most reliable starting point — whether or not urolithin A turns out to be the right tool for what you're trying to address.